Literature DB >> 19329578

Cancer stem cells in brain tumor biology.

J N Rich1, C E Eyler.   

Abstract

Tumors are aberrant organ systems containing a complex interplay between the neoplastic compartment and recruited vascular, inflammatory, and stromal elements. Furthermore, most cancers display a hierarchy of differentiation states within the tumor cell population. Molecular signals that drive tumor formation and maintenance commonly overlap with those involved in normal development and wound responses--two processes in which normal stem cells function. It is therefore not surprising that cancers invoke stem cell programs that promote tumor malignancy. Stem-cell-like cancer cells (or cancer stem cells) need not be derived from normal stem cells but may be subjected to evolutionary pressures that select for the capacity to self-renew extensively or differentiate depending on conditions. Current cancer model systems may not fully recapitulate the cellular complexity of cancers, perhaps partially explaining the lack of power of these models in predicting clinical outcomes. New methods are enabling researchers to identify and characterize cancer stem cells. Our laboratory focuses on the roles of brain tumor stem cells in clinically relevant tumor biology, including therapeutic resistance, angiogenesis, and invasion/metastasis. We hope that these studies will translate into improved diagnostic, prognostic, and therapeutic approaches for these lethal cancers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19329578      PMCID: PMC2822444          DOI: 10.1101/sqb.2008.73.060

Source DB:  PubMed          Journal:  Cold Spring Harb Symp Quant Biol        ISSN: 0091-7451


  75 in total

1.  Direct isolation of human central nervous system stem cells.

Authors:  N Uchida; D W Buck; D He; M J Reitsma; M Masek; T V Phan; A S Tsukamoto; F H Gage; I L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

2.  AC133 antigen as a prognostic factor in acute leukemia.

Authors:  S T Lee; J H Jang; Y H Min; J S Hahn; Y W Ko
Journal:  Leuk Res       Date:  2001-09       Impact factor: 3.156

3.  Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors.

Authors:  Joo Mi Yi; Hsing-Chen Tsai; Sabine C Glöckner; Steven Lin; Joyce E Ohm; Hari Easwaran; C David James; Joseph F Costello; Gregory Riggins; Charles G Eberhart; John Laterra; Angelo L Vescovi; Nita Ahuja; James G Herman; Kornel E Schuebel; Stephen B Baylin
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

4.  Cell cycle-dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, and melanoma cell lines.

Authors:  Marie Jaksch; Jorge Múnera; Ruchi Bajpai; Alexey Terskikh; Robert G Oshima
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

5.  Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells.

Authors:  Zeng-Jie Yang; Tammy Ellis; Shirley L Markant; Tracy-Ann Read; Jessica D Kessler; Melissa Bourboulas; Ulrich Schüller; Robert Machold; Gord Fishell; David H Rowitch; Brandon J Wainwright; Robert J Wechsler-Reya
Journal:  Cancer Cell       Date:  2008-08-12       Impact factor: 31.743

6.  Presence of pluripotent CD133+ cells correlates with malignancy of gliomas.

Authors:  Niklas Thon; Karin Damianoff; Jemima Hegermann; Stefan Grau; Bjarne Krebs; Oliver Schnell; Jörg-Christian Tonn; Roland Goldbrunner
Journal:  Mol Cell Neurosci       Date:  2008-08-07       Impact factor: 4.314

Review 7.  A philosophy of anti-infectives as a guide in the search for new drugs for tuberculosis.

Authors:  Carl Nathan; Ben Gold; Gang Lin; Melanie Stegman; Luiz Pedro Sorio de Carvalho; Omar Vandal; Aditya Venugopal; Ruslana Bryk
Journal:  Tuberculosis (Edinb)       Date:  2008-08       Impact factor: 3.131

Review 8.  The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells.

Authors:  Scott Bidlingmaier; Xiaodong Zhu; Bin Liu
Journal:  J Mol Med (Berl)       Date:  2008-06-06       Impact factor: 4.599

9.  Mutant prominin 1 found in patients with macular degeneration disrupts photoreceptor disk morphogenesis in mice.

Authors:  Zhenglin Yang; Yali Chen; Concepcion Lillo; Jeremy Chien; Zhengya Yu; Michel Michaelides; Martin Klein; Kim A Howes; Yang Li; Yuuki Kaminoh; Haoyu Chen; Chao Zhao; Yuhong Chen; Youssef Tawfik Al-Sheikh; Goutam Karan; Denis Corbeil; Pascal Escher; Shin Kamaya; Chunmei Li; Samantha Johnson; Jeanne M Frederick; Yu Zhao; Changguan Wang; D Joshua Cameron; Wieland B Huttner; Daniel F Schorderet; Frances L Munier; Anthony T Moore; David G Birch; Wolfgang Baehr; David M Hunt; David S Williams; Kang Zhang
Journal:  J Clin Invest       Date:  2008-08       Impact factor: 14.808

10.  Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma.

Authors:  Ulrich Schüller; Vivi M Heine; Junhao Mao; Alvin T Kho; Allison K Dillon; Young-Goo Han; Emmanuelle Huillard; Tao Sun; Azra H Ligon; Ying Qian; Qiufu Ma; Arturo Alvarez-Buylla; Andrew P McMahon; David H Rowitch; Keith L Ligon
Journal:  Cancer Cell       Date:  2008-08-12       Impact factor: 31.743

View more
  33 in total

1.  Leptin deficiency suppresses MMTV-Wnt-1 mammary tumor growth in obese mice and abrogates tumor initiating cell survival.

Authors:  Qiao Zheng; Sarah M Dunlap; Jinling Zhu; Erinn Downs-Kelly; Jeremy Rich; Stephen D Hursting; Nathan A Berger; Ofer Reizes
Journal:  Endocr Relat Cancer       Date:  2011-07-11       Impact factor: 5.678

2.  PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas.

Authors:  Hongwu Zheng; Haoqiang Ying; Ruprecht Wiedemeyer; Haiyan Yan; Steven N Quayle; Elena V Ivanova; Ji-Hye Paik; Hailei Zhang; Yonghong Xiao; Samuel R Perry; Jian Hu; Anant Vinjamoori; Boyi Gan; Ergun Sahin; Milan G Chheda; Cameron Brennan; Y Alan Wang; William C Hahn; Lynda Chin; Ronald A DePinho
Journal:  Cancer Cell       Date:  2010-05-18       Impact factor: 31.743

Review 3.  Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy.

Authors:  Jiao Zhang; Yan-Hua Chen; Qun Lu
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

4.  Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate.

Authors:  Koos E Hovinga; Fumiko Shimizu; Rong Wang; Georgia Panagiotakos; Maartje Van Der Heijden; Hamideh Moayedpardazi; Ana Sofia Correia; Denis Soulet; Tamara Major; Jayanthi Menon; Viviane Tabar
Journal:  Stem Cells       Date:  2010-06       Impact factor: 6.277

5.  QKI deficiency maintains glioma stem cell stemness by activating the SHH/GLI1 signaling pathway.

Authors:  Bo Han; Ruijia Wang; Yongjie Chen; Xiangqi Meng; Pengfei Wu; Ziwei Li; Chunbin Duan; Qingbin Li; Yang Li; Shihong Zhao; Chuanlu Jiang; Jinquan Cai
Journal:  Cell Oncol (Dordr)       Date:  2019-07-10       Impact factor: 6.730

6.  New strategies in the molecular targeting of glioblastoma: how do you hit a moving target?

Authors:  Timothy F Cloughesy; Paul S Mischel
Journal:  Clin Cancer Res       Date:  2011-01-01       Impact factor: 12.531

Review 7.  Molecular pathogenesis of sporadic melanoma and melanoma-initiating cells.

Authors:  Yunyi Kong; Suresh M Kumar; Xiaowei Xu
Journal:  Arch Pathol Lab Med       Date:  2010-12       Impact factor: 5.534

8.  Qki deficiency maintains stemness of glioma stem cells in suboptimal environment by downregulating endolysosomal degradation.

Authors:  Takashi Shingu; Allen L Ho; Liang Yuan; Xin Zhou; Congxin Dai; Siyuan Zheng; Qianghu Wang; Yi Zhong; Qing Chang; James W Horner; Brandon D Liebelt; Yu Yao; Baoli Hu; Yiwen Chen; Gregory N Fuller; Roeland G W Verhaak; Amy B Heimberger; Jian Hu
Journal:  Nat Genet       Date:  2016-11-14       Impact factor: 38.330

9.  Inhibitory activities of trichostatin a in U87 glioblastoma cells and tumorsphere-derived cells.

Authors:  Felipe de Almeida Sassi; Lílian Caesar; Mariane Jaeger; Carolina Nör; Ana Lucia Abujamra; Gilberto Schwartsmann; Caroline Brunetto de Farias; Algemir Lunardi Brunetto; Patrícia Luciana da Costa Lopez; Rafael Roesler
Journal:  J Mol Neurosci       Date:  2014-01-25       Impact factor: 3.444

10.  Targeting A20 decreases glioma stem cell survival and tumor growth.

Authors:  Anita B Hjelmeland; Qiulian Wu; Sarah Wickman; Christine Eyler; John Heddleston; Qing Shi; Justin D Lathia; Jennifer Macswords; Jeongwu Lee; Roger E McLendon; Jeremy N Rich
Journal:  PLoS Biol       Date:  2010-02-23       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.